



CASE 4-20921/A

Docket Number		4-20921/A
FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10		
EL138342775US Express Mail Label Number		March 12, 2001 Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1615

WAGNER ET AL.

Examiner: Di Nola Baron, L.

APPLICATION NO: 09/202,805

FILED: MAY 7, 1999

FOR: SOLID ORAL DOSAGE FORMS OF VALSARTAN

Assistant Commissioner for Patents
Washington, D.C. 20231

FEE LETTER FOR INFORMATION DISCLOSURE STATEMENT


Sir:

Please charge Deposit Account No. 19-0134 in the name of Novartis Corporation in the amount of \$180 for payment of the fee pursuant to 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(c).

An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis Corporation.

Respectfully submitted,

Novartis Corporation
Patent and Trademark Dept.
564 Morris Avenue
Summit, NJ 07901-1027
(908) 522-6807
Date: March 12, 2001



Diane Tso
Attorney for Applicants
Reg. No. 46,012